CGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compugen Ltd (CGEN) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as a bullish technical setup and a favorable analyst rating, the lack of recent significant news, insider selling activity, and poor financial performance in the latest quarter make this stock a hold rather than a buy.
The stock shows a bullish technical setup with MACD above 0, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and RSI indicating overbought conditions at 89.928. However, the price is near resistance levels (R1: 2.848, R2: 3.03), suggesting limited short-term upside.
Bullish technical indicators.
Analyst rating with a 'Buy' recommendation and a $6 price target, citing the company's unique TIGIT design as a competitive advantage.
Insider selling activity has increased by 177.02% over the last month.
Poor financial performance in 2025/Q4, with net income dropping -1029.30% YoY and EPS down -942.86% YoY.
No recent news or significant trading trends to support a strong buy case.
In 2025/Q4, revenue increased significantly by 4477.29% YoY, but net income dropped -1029.30% YoY, and EPS fell -942.86% YoY. Gross margin improved to 94.75, up 75.11% YoY, indicating operational efficiency but poor profitability.
Lake Street analyst Chad Messer initiated coverage with a 'Buy' rating and a $6 price target, highlighting the company's unique TIGIT design as a competitive advantage in the oncology space.
